Gefitinib Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets:
Available Strengths: 250 mg
Reference Brands: Iressa® (EU & US)
Category: Oncology Cancer Care
Gefitinib is available in Oral Tablets: and strengths such as 250 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Gefitinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Gefitinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Gefitinib is a targeted oral therapy used in the treatment of advanced non-small cell lung cancer (NSCLC) with confirmed EGFR mutations. Marketed under the brand name Iressa®, Gefitinib is approved in the EU and US and is widely available as 250 mg tablets. It is an EGFR tyrosine kinase inhibitor that blocks signals promoting tumor cell growth and proliferation. Gefitinib is an essential product in oncology therapy protocols and is frequently used as a first-line treatment for eligible NSCLC patients. Ideal for B2B pharmaceutical distributors seeking high-demand oncology medications in global regulated markets.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
